본문영역 바로가기
ABL Bio - medicine for A Better Life
About Us
Who We Are
History
Corporate Identity
Leadership
Contact Us
Platform & Strategies
Platform
Oncology Strategy
CNS Disease Strategy
ADC Strategy
Publications
Pipeline
Overview
ABL301
ABL503
ABL111
ABL102
ABL103
ABL104
ABL105
ABL602
ABL501
Investors & Media
Public Disclosure
Stock Information
Finance Information
Notice
News
Document & Materials
Careers
Core Competencies
Benefits
Recruitment
Recruiting Process
KOR
ENG
모바일 메뉴 보기
Investors & Media
News
Home
Investors & Media
News
[머니투데이] 세계 최초 치매치료제 승인, ABL바이오 BBB 투과기술 주목받나
2021-06-08
ablbio
https://news.mt.co.kr/mtview.php?no=2021060808380384891
list
PREV
ABL Bio Anticipates Acceleration of ABL001 Global Studies and Cancer Immunotherapy Pipeline Following TRIGR Therapeutics Merger
NEXT
ABL Bio to Present New Preclinical Data on 'Grabody-B' at BBB Summit
ABL Bio
About Us
Who We Are
History
Corporate Identity
Leadership
Contact Us
Platform & Strategies
Platform
Oncology Strategy
CNS Disease Strategy
ADC Strategy
Publications
Pipeline
Overview
ABL301
ABL503
ABL111
ABL102
ABL103
ABL104
ABL105
ABL602
ABL501
Investors & Media
Public Disclosure
Stock Information
Finance Information
Notice
News
Document & Materials
Careers
Core Competencies
Benefits
Recruitment
Recruiting Process
메뉴닫기